 |
138 Diseases |  |
94 Trials |
|
94 Trials |  |
2090 News |  |
| «12...21222324252627282930313233» |
- leuprolide acetate for depot suspension / Generic mfg., docetaxel / Generic mfg.
Trial primary completion date: A Registry for Patients Treated on the Clinical Trial TAX 3503 (clinicaltrials.gov) - May 19, 2016
P3, N=19, Enrolling by invitation, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Mar 2016 --> Mar 2018
- Imjudo (tremelimumab) / AstraZeneca, Pfizer
Trial completion, Combination therapy: CP-675,206 With Neoadjuvant Hormone Therapy in Patients With High Risk Prostate Cancer (clinicaltrials.gov) - May 16, 2016
P1/2, N=8, Completed, Sponsor: AstraZeneca
Trial primary completion date: Mar 2016 --> Mar 2018 No longer recruiting --> Completed
- leuprolide acetate for depot suspension / Generic mfg., cyclophosphamide / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date: LUPRON: GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic Diseases (clinicaltrials.gov) - May 13, 2016
P3, N=14, Terminated, Sponsor: Joseph Mccune
No longer recruiting --> Completed N=75 --> 14 | Recruiting --> Terminated | Trial primary completion date: May 2016 --> Oct 2015
- ||||| Erleada (apalutamide) / J&J
New P2 trial: c15-164: AASUR in High Risk Prostate Cancer (clinicaltrials.gov) - May 13, 2016
P2, N=58, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
- | Erleada (apalutamide) / J&J
New P2 trial: Apalutamide and Leuprolide in Intermediate and High-risk Prostate Cancer (clinicaltrials.gov) - May 12, 2016
P2, N=57, Not yet recruiting, Sponsor: Case Comprehensive Cancer Center
- Estrace topical (estradiol) / AbbVie, Estrace (estradiol) / AbbVie
Trial primary completion date: Neurophysiology of Postpartum Depression in an Experimental Model of Pregnancy and Parturition (clinicaltrials.gov) - May 6, 2016
P=N/A, N=30, Recruiting, Sponsor: University of North Carolina, Chapel Hill
N=75 --> 14 | Recruiting --> Terminated | Trial primary completion date: May 2016 --> Oct 2015 Trial primary completion date: Feb 2016 --> Oct 2016
- leuprolide acetate for depot suspension / Generic mfg., bicalutamide / Generic mfg., docetaxel / Generic mfg.
Trial initiation date, Metastases: oligo-mets: A Study of Definitive Therapy to Treat Prostate Cancer (clinicaltrials.gov) - May 5, 2016
P0, N=33, Not yet recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Trial primary completion date: Feb 2016 --> Oct 2016 Initiation date: Mar 2016 --> Jun 2016
- | Firmagon (degarelix) / Astellas, Ferring
Trial completion, Trial primary completion date: Degarelix in the Treatment of Endometriosis Recurrence (clinicaltrials.gov) - Apr 27, 2016
P3, N=100, Completed, Sponsor: Centre for Endocrinology and Reproductive Medicine, Italy
Initiation date: Mar 2016 --> Jun 2016 Recruiting --> Completed | Trial primary completion date: Jul 2015 --> Mar 2016
- goserelin acetate / Generic mfg., leuprolide acetate for depot suspension / Generic mfg., triptorelin / Generic mfg.
New P4 trial, Metastases: Comparison of Trelstar Versus Lupron or Zoladex in Advanced Prostate Cancer (clinicaltrials.gov) - Apr 25, 2016
P4, N=41, Terminated, Sponsor: Pharmatech
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed: NEOADAPT: NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer (clinicaltrials.gov) - Apr 22, 2016
P2, N=32, Active, not recruiting, Sponsor: Midwestern Regional Medical Center
Recruiting --> Completed | Trial primary completion date: Jul 2015 --> Mar 2016 Not yet recruiting --> Active, not recruiting
- ||||| leuprolide acetate for depot suspension / Generic mfg.
Enrollment closed, Trial primary completion date: A Study of the Effect of Enantone LP 11.25 mg (Leuprorelin) on the Histological Progression of Indolent Prostate Cancer (clinicaltrials.gov) - Apr 21, 2016
P3, N=120, Active, not recruiting, Sponsor: Takeda
Not yet recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2016 --> Jul 2016
- | New P2 trial, Surgery, Metastases: Androgen Deprivation Therapy or Androgen Deprivation Therapy Plus Definitive Treatment (Radiation or Surgery) (clinicaltrials.gov) - Apr 19, 2016
P2, N=200, Recruiting, Sponsor: Fudan University
- leuprolide acetate for depot suspension / Generic mfg., bicalutamide / Generic mfg.
Trial termination: Implant and External Radiation for Prostate Cancer With or Without Hormonal Therapy: A Prospective Randomized Trial (clinicaltrials.gov) - Apr 14, 2016
P3, N=6, Terminated, Sponsor: Schiffler Cancer Center
Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2016 --> Jul 2016 Completed --> Terminated; poor accrual
- | goserelin acetate / Generic mfg., leuprolide acetate for depot suspension / Generic mfg., docetaxel / Generic mfg.
Enrollment closed, Surgery: Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer (clinicaltrials.gov) - Apr 14, 2016
P3, N=788, Active, not recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Completed --> Terminated; poor accrual Recruiting --> Active, not recruiting
- leuprolide acetate for depot suspension / Generic mfg.
New P3 trial: Treatment of Uterine Fibroids With Magnetic Resonance Guided High Intensity Focused Ultrasound (clinicaltrials.gov) - Apr 13, 2016
P3, N=30, Not yet recruiting, Sponsor: Thunder Bay Regional Research Institute
- prednisone / Generic mfg., abiraterone acetate / Generic mfg.
Trial completion: Abiraterone Prednisone and Hormonal Therapy Before and During Radiation Therapy in Localized Prostate Cancer (clinicaltrials.gov) - Mar 29, 2016
P2, N=25, Completed, Sponsor: University of Washington
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- goserelin acetate / Generic mfg., leuprolide acetate for depot suspension / Generic mfg., bicalutamide / Generic mfg.
Enrollment change, Trial withdrawal, Trial primary completion date: Clinical Trial Comparing 3-D RT vs. IMRT in Post- Prostatectomy Prostate Cancer Patients (clinicaltrials.gov) - Mar 24, 2016
P2, N=0, Withdrawn, Sponsor: University of Kansas Medical Center
Active, not recruiting --> Completed N=100 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Apr 2018 --> Feb 2016
- leuprolide acetate for depot suspension / Generic mfg., bicalutamide / Generic mfg., docetaxel / Generic mfg.
New trial, Metastases: oligo-mets: A Study of Definitive Therapy to Treat Prostate Cancer (clinicaltrials.gov) - Mar 23, 2016
P0, N=33, Not yet recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
- | leuprolide acetate for depot suspension / Generic mfg.
New P4 trial: Efficacy and Safety of Medication Used to Stimulate Ovulation (clinicaltrials.gov) - Mar 22, 2016
P4, N=666, Recruiting, Sponsor: Create Fertility Center
- || Kepivance (palifermin) / SOBI, Amgen, Firmagon (degarelix) / Astellas, Ferring
Trial primary completion date: Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) - Mar 16, 2016
P2, N=120, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
N=100 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Apr 2018 --> Feb 2016 Trial primary completion date: Dec 2016 --> Dec 2017
- |||||| Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Enrollment open: A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids (clinicaltrials.gov) - Mar 16, 2016
P3, N=288, Recruiting, Sponsor: Takeda
Trial primary completion date: Dec 2016 --> Dec 2017 Not yet recruiting --> Recruiting
- leuprolide acetate for depot suspension / Generic mfg., anastrozole / Generic mfg.
Trial primary completion date: Study of the Effect of Testosterone and Estradiol on NP Responses to Acute and Chronic Salt Loading (clinicaltrials.gov) - Mar 10, 2016
P0, N=0, Withdrawn, Sponsor: Massachusetts General Hospital
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2017 --> Feb 2016
- Natrecor (nesiritide) / J&J
Trial primary completion date: Testosterone Regulation of the Natriuretic Peptide System (clinicaltrials.gov) - Mar 10, 2016
P=N/A, N=0, Withdrawn, Sponsor: Massachusetts General Hospital
Trial primary completion date: Jun 2017 --> Feb 2016 Trial primary completion date: Feb 2019 --> Feb 2016
- Livial (tibolone) / Organon
Trial initiation date, Trial primary completion date: Psychological Impact of Amenorrhea in Women With Endometriosis (clinicaltrials.gov) - Mar 9, 2016
P4, N=50, Not yet recruiting, Sponsor: University of Cagliari
Trial primary completion date: Feb 2019 --> Feb 2016 Initiation date: Oct 2015 --> Jun 2016 | Trial primary completion date: Apr 2016 --> Dec 2016
- | Suprefact (buserelin acetate) / Sanofi, Firmagon (degarelix) / Astellas, Ferring
Enrollment closed: Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer (clinicaltrials.gov) - Mar 9, 2016
P3, N=1538, Active, not recruiting, Sponsor: Radiation Therapy Oncology Group
Initiation date: Oct 2015 --> Jun 2016 | Trial primary completion date: Apr 2016 --> Dec 2016 Recruiting --> Active, not recruiting
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas
Enrollment closed: Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM) (clinicaltrials.gov) - Mar 8, 2016
P2, N=38, Active, not recruiting, Sponsor: Duke University
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||||| Firmagon (degarelix) / Astellas, Ferring
Enrollment open, Adverse events, Metastases: PRONOUNCE: A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease (clinicaltrials.gov) - Mar 4, 2016
P3, N=900, Recruiting, Sponsor: Ferring Pharmaceuticals
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Emcyt (estramustine) / Pfizer, Nippon Shinyaku
Trial primary completion date: Chemotherapy and Hormone Therapy in Treating Patients With Prostate Cancer (clinicaltrials.gov) - Feb 29, 2016
P2, N=63, Active, not recruiting, Sponsor: University of Massachusetts, Worcester
Not yet recruiting --> Recruiting Trial primary completion date: Feb 2016 --> Feb 2017
- leuprolide acetate for depot suspension / Generic mfg.
Trial completion: Clinical Trial for Prostate Cancer (clinicaltrials.gov) - Feb 27, 2016
P3, N=0, Completed, Sponsor: Oakwood Laboratories, LLC
Trial primary completion date: Feb 2016 --> Feb 2017 No longer recruiting --> Completed
- leuprolide acetate for depot suspension / Generic mfg.
Trial primary completion date: Preservation of Ovarian Function After Hematopoietic Cell Transplant (clinicaltrials.gov) - Feb 24, 2016
P2, N=47, Active, not recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
No longer recruiting --> Completed Trial primary completion date: Dec 2015 --> Oct 2014
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P2 trial: NEOADAPT: NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer (clinicaltrials.gov) - Feb 24, 2016
P2, N=32, Not yet recruiting, Sponsor: Midwestern Regional Medical Center
- || leuprolide acetate for depot suspension / Generic mfg.
Trial primary completion date: Leuprorelin Acetate SR 11.25 mg for Injection Specified Drug-use Survey "Long-term Use Survey on Premenopausal Breast Cancer Patients (96 Weeks)" (clinicaltrials.gov) - Feb 17, 2016
P=N/A, N=651, Completed, Sponsor: Takeda
Trial primary completion date: Dec 2015 --> Oct 2014 Trial primary completion date: Jun 2010 --> Mar 2010
- ||| Avastin (bevacizumab) / Roche
Enrollment closed, Metastases: BOOSTER: Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer (clinicaltrials.gov) - Feb 17, 2016
P2, N=160, Active, not recruiting, Sponsor: Japan Breast Cancer Research Group
Trial primary completion date: Jun 2010 --> Mar 2010 Recruiting --> Active, not recruiting
- Xtandi (enzalutamide capsule) / Pfizer, Astellas
Trial primary completion date, Metastases: LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer (clinicaltrials.gov) - Feb 9, 2016
P2, N=92, Recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
Recruiting --> Active, not recruiting Trial primary completion date: Jan 2016 --> Dec 2016
- | everolimus / Generic mfg.
Enrollment change, Trial primary completion date: S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer (clinicaltrials.gov) - Jan 27, 2016
P3, N=1900, Recruiting, Sponsor: Southwest Oncology Group
Trial primary completion date: Jan 2016 --> Dec 2016 N=3500 --> 1900 | Trial primary completion date: Mar 2016 --> Dec 2022
- |||||||||| Firmagon (degarelix) / Astellas, Ferring
New P3 trial, Adverse events, Metastases: PRONOUNCE: A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease (clinicaltrials.gov) - Jan 26, 2016
P3, N=900, Not yet recruiting, Sponsor: Ferring Pharmaceuticals
- || stapuldencel-T (DCVAC/PCa) / Sotio
Trial primary completion date, Combination therapy, Metastases: ASN-002-IL: Phase II Study of DCVAC/PCa Added to Hormone Therapy for Men With Metastatic Prostate Cancer (clinicaltrials.gov) - Jan 17, 2016
P2, N=63, Active, not recruiting, Sponsor: Sotio a.s.
N=3500 --> 1900 | Trial primary completion date: Mar 2016 --> Dec 2022 Trial primary completion date: Oct 2013 --> Dec 2015
- |||||||||| Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
New P3 trial: A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids (clinicaltrials.gov) - Jan 14, 2016
P3, N=288, Not yet recruiting, Sponsor: Takeda
- docetaxel / Generic mfg.
Enrollment change, Trial initiation date, Trial primary completion date, Metastases: Docetaxel, Radiation Therapy, and Hormone Therapy in Treating Patients With Locally Advanced Prostate Cancer (clinicaltrials.gov) - Dec 29, 2015
P1, N=20, Active, not recruiting, Sponsor: David T. Marshall
Trial primary completion date: Oct 2013 --> Dec 2015 N=36 --> 20 | Initiation date: Jul 2004 --> Jul 2010 | Trial primary completion date: Dec 2012 --> Jan 2011
- Orgalutran (ganirelix acetate) / Organon
Trial completion: Follicle-Stimulating Hormone (FSH) and the Onset of Puberty (clinicaltrials.gov) - Dec 5, 2015
P=N/A, N=11, Completed, Sponsor: University of Utah
N=36 --> 20 | Initiation date: Jul 2004 --> Jul 2010 | Trial primary completion date: Dec 2012 --> Jan 2011 Suspended --> Completed
- | Ibrance (palbociclib) / Pfizer
New P2 trial, Combination therapy, Metastases: A Study of Palbociclib With Exemestane Plus GnRH Versus Capecitabine in Premenopausal Women With HR+ MBC (clinicaltrials.gov) - Oct 30, 2015
P2, N=122, Not yet recruiting, Sponsor: Samsung Medical Center
- Xtandi (enzalutamide capsule) / Pfizer, Astellas
Enrollment open: Trial of Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate Cancer (clinicaltrials.gov) - Oct 29, 2015
P2, N=53, Recruiting, Sponsor: University of California, San Francisco
Suspended --> Completed Not yet recruiting --> Recruiting
- || anastrozole/levonorgestrel (BAY 98-7196) / Bayer
Trial primary completion date: Bay98-7196, Dose Finding / POC Study (clinicaltrials.gov) - Oct 22, 2015
P2b, N=318, Recruiting, Sponsor: Bayer
Not yet recruiting --> Recruiting Trial primary completion date: May 2016 --> Sep 2016
- Yervoy (ipilimumab) / Ono Pharma, BMS
Trial primary completion date: Ipilimumab + Androgen Depravation Therapy in Prostate Cancer (clinicaltrials.gov) - Oct 22, 2015
P2, N=48, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: May 2016 --> Sep 2016 Trial primary completion date: Jun 2016 --> Jun 2017
- Xtandi (enzalutamide capsule) / Pfizer, Astellas
Enrollment open: Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer (clinicaltrials.gov) - Oct 22, 2015
P2, N=56, Recruiting, Sponsor: University of Colorado, Denver
Trial primary completion date: Jun 2016 --> Jun 2017 Not yet recruiting --> Recruiting
- | Yervoy (ipilimumab) / Ono Pharma, BMS
Trial completion, Trial primary completion date, IO biomarker: Neoadjuvant Ipilimumab in Prostate Cancer (clinicaltrials.gov) - Oct 15, 2015
P2a, N=19, Completed, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial primary completion date: Sep 2016 --> Oct 2015
- Livial (tibolone) / Organon
Trial initiation date: Psychological Impact of Amenorrhea in Women With Endometriosis (clinicaltrials.gov) - Sep 22, 2015
P4, N=50, Not yet recruiting, Sponsor: University of Cagliari
Active, not recruiting --> Completed | Trial primary completion date: Sep 2016 --> Oct 2015 Initiation date: Apr 2015 --> Oct 2015
- || Sutent (sunitinib) / Pfizer
Trial primary completion date: Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy (clinicaltrials.gov) - Sep 16, 2015
P2, N=64, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Initiation date: Apr 2015 --> Oct 2015 Trial primary completion date: Dec 2015 --> Dec 2017
- | cabazitaxel / Generic mfg.
New P2 trial: ACDC-RP: Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC Trial) (clinicaltrials.gov) - Sep 8, 2015
P2, N=74, Not yet recruiting, Sponsor: University Health Network, Toronto
- |||||| Herceptin (trastuzumab) / Roche, Kisqali (ribociclib) / Novartis, Perjeta (pertuzumab) / Roche
Enrollment open, Trial initiation date, Trial primary completion date, Combination therapy, Metastases: Detect V / CHEVENDO (Chemo vs. Endo) (clinicaltrials.gov) - Sep 2, 2015
P3, N=270, Recruiting, Sponsor: Prof. W. Janni
Trial primary completion date: Dec 2015 --> Dec 2017 Not yet recruiting --> Recruiting | Initiation date: Apr 2015 --> Sep 2015 | Trial primary completion date: Mar 2021 --> Sep 2021